Kornimate/medical-research-clean huggingface dataset:
comparison of nebivolol and metoprolol with exercise and angiotensin ii in hypertensive patients

Conditions: Hypertension

Summary: the purpose of this study is to determine if nebivolol a) attenuates the angiotensin ii (ang ii)-induced increase in oxidative stress, thereby attenuating ang ii-induced vasoconstriction; and b) attenuates sympathetic mediated vasoconstriction during exercise, thereby reducing functional skeletal muscle ischemia in hypertensive patients.

in 40 untreated, stage i hypertensive subjects, investigators will measure sympathetic nerve activity (microneurography); total forearm blood flow (high-resolution ultrasonography); skeletal muscle oxygenation (near infrared spectroscopy); plasma f2-isoprostanes; cardiac output (non-invasive impedance plethysmography); and blood pressure at baseline and after a) rhythmic handgrip exercise at 30% of maximal voluntary contraction alone for 3 minutes, b) rhythmic handgrip at the same intensity of exercise plus lower body negative pressure (lbnp) to activate sympathetic nerve activity (sna) for 2 minutes, and c) during intravenous infusion of angiotensin ii at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose. each subject will then be randomized to receive 12 weeks of nebivolol (bystolic, 5-20 mg/day) or metoprolol succinate (toprol xl, 100-300 mg/day), using a randomized crossover design. there will be a 2-week washout period between the two treatment periods. during drug treatment, blood pressure will be monitored every 4 weeks and the doses of nebivolol and metoprolol will be titrated to keep bp \<140/90 mmhg. sna, total forearm blood flow, skeletal muscle blood flow, muscle oxygenation, cardiac output, and blood pressure responses to nebivolol will be compared to responses during metoprolol in the same subjects.

Eligibility criteria:
inclusion criteria: * stage i hypertension (140-159/90-99 mmhg) * men and women age 18-65 exclusion criteria: * congestive heart failure or coronary artery disease * blood pressure averaging \>159/99 mmhg or resting heart rate \< 55 bpm * serum creatinine \> 1.4 mg/dl * asthma or chronic obstructive pulmonary diseases * left ventricular hypertrophy by echocardiography or ecg * pregnancy * hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin * any history of substance abuse (other than tobacco) * concomitant drug treatment which raises endogenous nitric oxide levels such as nitrates or phosphodiesterase v inhibitors (viagra, levitra, or cialis) * history of symptomatic bradycardia or heart block

Keywords: hypertension blood pressure blood pressure medications metoprolol nebivolol handgrip exercise lower body negative pressure angiotensin ii sympathetic nerve activity flow mediated dilation nitric oxide microneurography
the value of 68ga-grazytracer pet in monitoring responses to immunotherapy of advanced soft tissue sarcomas

Conditions: Advanced Soft Tissue Sarcomas

Summary: this study aims to investigate the value of 68ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.

the investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. all participants will undergo a 68ga-grazytracer pet/ct after 3 cycles of immunotherapy to evaluate response. the imaging response measurements will be compared with the histopathological or clinical assessment results as gold standard.

Eligibility criteria:
inclusion criteria: 1. pathological and clinical diagnosis of advanced soft tissue sarcomas, pathological types include: fibrosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, rhabdomyosarcoma, synovial sarcoma, alveolar soft-part sarcoma, leiomyosarcoma, clear cell sarcoma, malignant schwannoma, angiosarcoma. 2. consider immunotherapy or combined immunotherapy based on clinical judgement. 3. signed and dated informed consent form. 4. commitment to comply with research procedures and co-operation in the implementation of the full research process. 5. aged 6-80 years old. exclusion criteria: 1. patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. intestinal perforation, complete intestinal obstruction 3. pregnant women and women who may be pregnant, women who are breastfeeding. 4. non-compliant person

Keywords: 68ga-grazytracer pet/ct immunotherapy advanced soft tissue sarcomas
a clinical studyf of shr-1701 or placebo in combination with bp102 and xelox in the first-line treatment of mcrc

Conditions: Metastatic Colorectal Cancer (mCRC)

Summary: this is a two-arm, randomized, double-blinded, multicenter phase ii/iii clinical study to evaluate the safety and clinical efficacy of shr-1701 or placebo in combination with bp102 (biosimilar to bevacizumab) and xelox in first-line treatment of patients with mcrc.


Eligibility criteria:
inclusion criteria: 1. patients with unresectable recurrent or metastatic adenocarcinoma of the colon or rectum confirmed histologically 2. for subjects who have not previously received any systemic antitumor therapy and who have previously received neoadjuvant or adjuvant therapy, the first detection of recurrence or metastasis should be ≥12 months after the last administration of neoadjuvant or adjuvant therapy 3. at least 1 measurable lesion according to recist v1.1 4. the vital organs are functioning well 5. ecog score is 0 \~ 1 6. contraception was initiated from the signing of the informed consent until at least 6 months after the last dosing of the study drug exclusion criteria: 1. recurrent or metastatic lesions can be treated with radical surgery 2. presence of central nervous system or meningeal metastases; 3. moderate and severe ascites of clinical symptoms;uncontrolled or moderate or greater pleural effusion or pericardial effusion 4. poorly controlled hypertension (systolic blood pressure ≥140 mmhg and/or diastolic blood pressure ≥90 mmhg in the case of regular antihypertensive therapy) and prior hypertensive crisis or hypertensive encephalopathy 5. severe cardiovascular and cerebrovascular diseases;have clinical heart symptoms or diseases that are not well controlledsubjects with a history of myocardial infarction or unstable angina pectoris 6. subject with current interstitial pneumonia or interstitial lung disease, or with a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy 7. previous treatment with targeted t cell costimulatory molecules and immune checkpoint inhibitors;previous treatment with antiepidermal growth factor receptor or any antiangiogenic drug
extended release (er) niacin/laropiprant add on study (0524a-082)

Conditions: Dyslipidemia

Summary: the purpose of this study is to test the effect of mk0524a (niacin (+) laropiprant) on lowering bad cholesterol and raising good cholesterol.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older and on a stable dose of lipid therapy exclusion criteria: * patients lipid level is outside the recommended range * patients that are hiv positive
core stabilization versus routine routine exercises in pelvic girdle pain.

Conditions: Pelvic Girdle Pain

Summary: pregnancy induced pelvic girdle pain (pgp) is common complaint in pregnant women all over the world and it has a major impact on health and functioning as it decreases quality of life. the onset of pgp is usually seen at 17-19 week of gestation, with a peak of incidence at 24- 36 weeks. the purpose of this study is to compare the effects of stabilization exercises on pregnancy induced pelvic girdle pain and its effects on the activity levels as compare to the physiotherapy exercises that are routinely prescribed

the study is randomized controlled trial which will be conducted in the outpatient physical therapy department. patient with suspected pgp will be referred by midwives, physicians or directly contact to physiotherapist. sample size of 30 individual was calculated by using open epi tool with 95% confidence interval (ci) and 80% power. inclusion criteria for patients is 13-28 gestational weeks determined by special test include p4 test (posterior pelvic pain provocation) and faber test (flexion abduction and external rotation). individuals would be randomly allocated into two groups by sealed envelope method. assessment will be done at base line and 4th week by using nprs and pgp questionnaire. data will be analyzed by using spss version 21.

Eligibility criteria:
inclusion criteria: * women having pelvic girdle pain in 2nd trimester or 1st month of third trimester. * age between 20-40 years. * positive faber test (leg of patient is placed in figure of 4 and apply small amplitude oscillation are applied at end range of motion after stabilizing opposite side of pelvis. positive test elicits pain and limited rom) * positive p4 test (leg of patient is flexed at 90 degrees in supine position. sacrum is stabilized by one hand and axial pressure is applied along the femur by other hand. positive test elicits pain in si joint). exclusion criteria: * history of pelvic fractures and surgery * history of metabolic diseases. * radiculopathy

Keywords: core stability exercises pelvic girdle pain pregnancy physical therapy management
bioequivalency study of perindopril erbumine 8 mg tablet under fasted conditions

Conditions: Essential Hypertension

Summary: the objective of this study was to prove the bioequivalence of perindopril erbumine 8 mg tablets under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to perindopril or any comparable or similar product.
influence of non invasive mechanical ventilation on tissue perfusion in patients after cardiac surgery

Conditions: Heart Diseases; Coronary Artery Disease

Summary: this study evaluates whether noninvasive ventilation with continuous positive airway pressure affects tissue perfusion in patients after cardiac surgery.

patients submitted to open chest cardiac surgery will be enrolled after icu admission. these patients will be submitted to noninvasive mechanical ventilation with continuous positive airway pressure right after extubation and tissue perfusion markers (central venous oxygen saturation (svco2) and lactate) will be obtained via central venous catheter. noninvasive mechanical ventilation is a common resource in the icu to reduce extubation failures and to improve clinical outcomes, whether it can influence tissue perfusion remains unclear. this study evaluates whether noninvasive ventilation affects tissue perfusion and whether tissue perfusion markers in the icu are correlated with better clinical results for patients after heart surgery.

Eligibility criteria:
inclusion criteria: * presence of central venous catheter * invasive arterial pressure catheter * invasive mechanical ventilation exclusion criteria: * chronic obstructive pulmonary disease * morbid obesity * hemodynamic instability * spontaneous breathing * need of invasive mechanical ventilation for more than 24 hours * intolerance to noninvasive mechanical ventilation * extubation failure

Keywords: postoperative care postoperative period heart surgery
repetitive transcranial magnetic stimulation (rtms) for dystonia and tremor

Conditions: Dystonia; Tremor

Summary: the study will include subjects diagnosed with dystonic tremor (dt), essential tremor (et), and healthy controls in the age range of 21-80 years. electroencephalography (eeg) will be used as the primary outcome measure. transcranial magnetic stimulation (tms) will be used over the motor cortices or cerebellar cortices as an intervention that is expected to have short-term (less than an hour) electrophysiological effects.

the primary goal of this study is to compare differences in cortical activity of patients with tremor before and after applying a session of rtms. specifically, the investigators will apply rtms to the primary motor cortex (m1) as our group and others have shown abnormal function of the region. moreover, a study shows that targeting of m1 and the dorsal premotor cortex (dpmc) with rtms results in a trend towards improved clinical outcome in patients with focal hand dystonia and cervical dystonia. the central hypothesis of this study is that rtms can modify cortical oscillations in patient populations with tremor and that the investigators will be able to detect these changes with the use of electroencephalography (eeg). by applying inhibitory rtms to the motor cortices, the investigators may expect a shift in cortical oscillations towards normal activity.

Eligibility criteria:
inclusion criteria for dystonia and/or tremor: - diagnosis of dystonia and/or tremor according to the consensus statement of the movement disorders society exclusion criteria dystonia and/or tremor: * pregnancy * active seizure disorder * presence of a metallic object such as a pacemaker, implants, metal rods, and hearing aid * history of stroke inclusion criteria for healthy controls - there is no history of any neurological disorders. exclusion criteria for healthy controls * pregnancy * any neurological disorders * presence of a metallic body in their brain * history of stroke
capillary and venous lactate in emergency department patients

Conditions: Triage Category 3 (Urgent)

Summary: the objective of the present project is to study the accuracy of capillary blood level measured by handheld lactate analyzers when compared with the reference methods e.g.venepuncture blood gas analyzer sample.

background: increase in lactate levels (hyperlactataemia) is common in critically ill patients and it is a sensitive marker in early identification of patients who are critically ill. blood lactate is also a predictor of clinical outcomes. high level of lactate is associated with high mortality as well as increased morbidity. capillary blood sample is easy to collect, less painful, and its measurement using handheld device which may allow more rapid determination of test results in ed. this rapid lactate measurement could aid early recognition of patients at high risk of mortality and morbidity. however, the accuracy of this rapid capillary lactate measurement using handheld devices has not been well studied in ed patients. objective: to study the accuracy of capillary blood level measured by handheld lactate analyzers when compared with the reference methods e.g.venepuncture blood gas analyzer sample. study design: this is a prospective observational study of patients presenting to ed of prince of wales hospital (pwh). patients aged 18 or above who are triage category 3 presenting to ed will be recruited. capillary and venous blood samples will be collected. venous lactate levels will be measured by blood gas analyzer (siemens automatic qc rapid systems rapid point@500) and two hand-held lactate analyzers (statstrip xpress lactate meter and lactate scout + ). venous lactate levels measured by blood gas analyzer will be served as "reference method". capillary lactate levels will be analyzed by handheld lactate analyzer. we are aimed to recruited 240 patients. outcomes: the primary outcome is the accuracy of capillary blood level measured by handheld lactate analyzers when compared with the reference methods e.g. venepuncture blood gas analyzer sample. the secondary outcomes are: (1) compare the difference in values of venous lactate using blood gas analyzer and hand-held lactate analyzers, (2) compare values of capillary and venous lactate using hand-held lactate analyzers, (3) compare the reporting times of handheld and blood gas analyzer, and (4) compare values of capillary lactate using between the two hand-held lactate analyzers.

Eligibility criteria:
inclusion criteria: * aged 18 years or above who are triage category 3 in emergency department * presenting to emergency department between 9am and 4pm, monday to friday exclusion criteria: * aged below 18 years * pregnant

Keywords: capillary blood venous blood lactate emergency department
diagnosis of cancer using breath samples

Conditions: Cancer

Summary: the purpose of this study is to collect breath samples from healthy and cancer sick patients. the breath, collected to special bags, will be transferred to laboratories in the technion and analyzed using an electronic nose system developed in hossam haick's labs (chemical engineering, technion). the hypothesis is that based on the analysis of the chemical bio-markers present in the exhaled breath, cancer states can be distinguished from healthy subjects or before and after treatment, allowing a technique for diagnosis of cancer and/or cancer treatment.


Eligibility criteria:
inclusion criteria: * the cancer is local or homeostatic * the subject did not undergo surgery for tumor removal, chemotherapy or radiation treatment prior to first sampling * the subject signed an informed consent form exclusion criteria: * the subject is addicted to drugs or alcohol * the subject smoked in the last hour * there are communication problems with the subject

Keywords: cancer breast cancer colon cancer lung cancer
special drug use investigation of eylea for myopic choroidal neovascularization

Conditions: Choroidal Neovascularization

Summary: the objectives of this study are to investigate the safety and effectiveness of eylea.

this is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of myopic choroidal neovascularization. the investigator will have made the choice of treatment (eylea) as well as the decision to use eylea according the japanese package insert prior to enrolling the patient in this study. the observation period for each patient starts when therapy with eylea is initiated. the enrollment period is 2 years. patients will be followed for a time period of 1 years or until it is no longer possible (e.g. lost to follow-up within the 1 year ). in total, 300 patients will be recruited. for each patient, data are collected as defined in the electronic case report form (ecrf) at the initial visit, follow-up visits and final visit, either by routine clinical visits (as per investigators routine practice) .

Eligibility criteria:
inclusion criteria: * patients who start eylea treatment for mcnv(myopic choroidal neovascularization). exclusion criteria: * patients who have already received eylea treatment.

Keywords: aflibercept anti-vegf
the study of mesenchymal stem cells treat autoimmune pulmonary alveolar proteinosis in vitro

Conditions: Pulmonary Alveolar Proteinosis(PAP)

Summary: autoimmune pulmonary alveolar proteinosis (apap) is a respiratory disease characterized by massive deposition of pulmonary surfactant in the alveoli, involving a variety of immune cells and factor disorders. however, there are certain limits in treatment at present. mscs can improve the microenvironment in the alveoli by regulating immunity, thereby achieving a good therapeutic effect. the purpose of this study is to use the lavage fluid obtained after whole lung lavage with apap to isolate alveolar macrophages, and to use msc to complete the verification of the efficacy of apap primary alveolar macrophages in vitro. a series of protocols including multi-factor detection, cell phenotype analysis and phagocytosis assay were used to evaluate the efficacy of mscs on alveolar macrophages.


Eligibility criteria:
inclusion criteria: 1. sign an informed consent form before any research-related activities; 2. no gender restrictions, age ≥18 years old, and ≤75 years old; 3. patients who need to receive whole lung lavage due to the needs of the disease, and the patient agrees to perform whole lung lavage. the standards are as follows: 1. the diagnosis of apap is clear, and the anti-gm-csf antibody in serum is greater than 5 μg/ml; 2. pao2 \<65 mmhg; 3. p(a-a)o2\>40 mmhg; 4. intrapulmonary shunt \>10%-12%. exclusion criteria: 1. suffering from multiple chronic respiratory diseases at the same time, including but not limited to chronic obstructive pulmonary disease, pulmonary fibrosis, and asthma; 2. various malignant tumors or a history of malignant tumors; 3. uncontrolled pulmonary or systemic infection; 4. severe other systemic diseases: acute myocardial infarction, unstable angina pectoris, liver cirrhosis, acute glomerulonephritis, etc.; 5. syphilis, hiv, hcv antibody positive; 6. patients with coagulation disorders who cannot perform bronchoscopy, such as hemophilia, giant platelet syndrome, thrombocytopenia, etc.; 7. severe renal impairment, serum creatinine \> 1.5 times the upper limit of normal; 8. liver disease or liver function damage: alt, ast, total bilirubin \> 2 times the upper limit of normal; 9. have any coexisting medical conditions or diseases that the investigators judge may impair the development of this trial; 10. social and mental disability, no legal capacity/limited capacity; 11. refuse to sign the informed consent. -

Keywords: apap cell therapy msc
patient's perspective on the evolution of hidradenitis suppurativa burden after secukinumab initiation

Conditions: Hidradenitis Suppurativa

Summary: the primary objective of this non-interventional study is to describe the evolution of hidradenitis suppurativa (hs) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.

this study is a prospective (primary data), national, descriptive, non-interventional, multicentre study conducted by medical practice and hospital-based dermatologists across different geographical regions in france. this real-world study does not change the physician-patient relationship or patient management or follow-up. physicians remain free with their prescriptions and patient follow-up procedures. in fact, secukinumab initiation and all treatment decisions will be made according to routine medical care and independently of study participation. recruited patients will be longitudinally followed-up for the duration of the study, up to 24 months (± 3 months) after secukinumab initiation or secukinumab treatment discontinuation before the end of the 24 months of follow-up (early discontinuation).

Eligibility criteria:
inclusion criteria: 1. male and female patients ≥ 18 years old, 2. patients who do not object to participation in the study, 3. diagnosis of hs clinically confirmed, 4. initiation of secukinumab treatment for hs in compliance with the summary of product characteristics, 5. the physician's decision to initiate secukinumab has been taken according to his/her own practice and regardless of study participation. exclusion criteria: 1. patients with any medical or psychological condition which, in the physician's opinion, may prevent participation in the study, 2. patients participating in a clinical trial.

Keywords: secukinumab hidradenitis suppurativa hs nis france